These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35987555)

  • 1. Treatment-Refractory Dravet Syndrome: Considerations for Novel Medications.
    Lopez JC; Pare JR; Blackmer AB; Orth LE
    J Pediatr Health Care; 2022; 36(5):479-488. PubMed ID: 35987555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.
    Guerrini R; Chiron C; Vandame D; Linley W; Toward T
    Epilepsia Open; 2024 Apr; 9(2):689-703. PubMed ID: 38427284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison.
    Devi N; Madaan P; Asrar MM; Sahu JK; Bansal D
    Seizure; 2021 Oct; 91():316-324. PubMed ID: 34274891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.
    Strzelczyk A; Schubert-Bast S
    CNS Drugs; 2022 Mar; 36(3):217-237. PubMed ID: 35156171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
    Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A
    Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing Landscape of Dravet Syndrome Management: An Overview.
    Samanta D
    Neuropediatrics; 2020 Apr; 51(2):135-145. PubMed ID: 32079034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Lattanzi S; Trinka E; Russo E; Del Giovane C; Matricardi S; Meletti S; Striano P; Damavandi PT; Silvestrini M; Brigo F
    Drugs; 2023 Oct; 83(15):1409-1424. PubMed ID: 37695433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome.
    Schoonjans AS; Ceulemans B
    Expert Rev Neurother; 2022 May; 22(5):351-364. PubMed ID: 33455486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
    Nabbout R; Mistry A; Zuberi S; Villeneuve N; Gil-Nagel A; Sanchez-Carpintero R; Stephani U; Laux L; Wirrell E; Knupp K; Chiron C; Farfel G; Galer BS; Morrison G; Lock M; Agarwal A; Auvin S;
    JAMA Neurol; 2020 Mar; 77(3):300-308. PubMed ID: 31790543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenfluramine (Fintepla) for Dravet syndrome.
    Med Lett Drugs Ther; 2021 Aug; 63(1630):126-128. PubMed ID: 34550111
    [No Abstract]   [Full Text] [Related]  

  • 11. Stiripentol for the treatment of seizures in Dravet syndrome.
    Eschbach K; Knupp KG
    Expert Rev Clin Pharmacol; 2019 May; 12(5):379-388. PubMed ID: 31017478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dravet syndrome: Treatment options and management of prolonged seizures.
    Cross JH; Caraballo RH; Nabbout R; Vigevano F; Guerrini R; Lagae L
    Epilepsia; 2019 Dec; 60 Suppl 3():S39-S48. PubMed ID: 31904119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stiripentol for the treatment of seizures associated with Dravet syndrome.
    Chiron C
    Expert Rev Neurother; 2019 Apr; 19(4):301-310. PubMed ID: 30900478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic advances in Dravet syndrome: a targeted literature review.
    Strzelczyk A; Schubert-Bast S
    Expert Rev Neurother; 2020 Oct; 20(10):1065-1079. PubMed ID: 32799683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
    Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
    Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dravet Syndrome: A Review of Current Management.
    Wheless JW; Fulton SP; Mudigoudar BD
    Pediatr Neurol; 2020 Jun; 107():28-40. PubMed ID: 32165031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice.
    Wirrell EC; Lagae L; Scheffer IE; Cross JH; Specchio N; Strzelczyk A
    Epilepsia Open; 2024 Oct; 9(5):1643-1657. PubMed ID: 38962968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients.
    Schoonjans A; Paelinck BP; Marchau F; Gunning B; Gammaitoni A; Galer BS; Lagae L; Ceulemans B
    Eur J Neurol; 2017 Feb; 24(2):309-314. PubMed ID: 27790834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy for Dravet Syndrome.
    Wallace A; Wirrell E; Kenney-Jung DL
    Paediatr Drugs; 2016 Jun; 18(3):197-208. PubMed ID: 26966048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualized treatment approaches: Fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome.
    Polster T
    Epilepsy Behav; 2019 Feb; 91():99-102. PubMed ID: 30269941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.